tbuckley/cabot-search huggingface dataset:
1517P Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study
Authors: G. Orsi, G. Notini, E. Lucin, M. Chiaravalli, M.C. Di Marco, E. Giommoni, S. Bozzarelli, R. Bianco, L. Pala, M. Macchini, C. Carconi, L.C. Leta, G. Tortora, C. Morelli, A. Spallanzani, I. Garajova, M. Scartozzi, L. Messineo, M. Falconi, M. Reni
Journal: Annals of Oncology (2024)
1540MO The patient voice: An analysis of real-world data using the recurrent respiratory papillomatosis foundation/CoRDS patient registry (RRPF/CoRDS)
Authors: S. Pai, W. OChieng, N. Hedlund, A. Martino, N. Chohan, M. Pawlak, E. Morais, K. McClellan
Journal: Annals of Oncology (2024)
1442P Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy
Authors: H. Osumi, T. Wakatsuki, N. Yamamoto, A. Ooki, K. Chin, H. Shoji, M. Ogura, I. Nakayama, H. Hirano, H. Hara, K. Minashi, E. Shinozaki, K. Kato, S. Kitano, K. Takeuchi, N. Boku, K. Yamaguchi, D. Takahari
Journal: Annals of Oncology (2024)
1461P Analysis of MET gene alterations in cfDNA samples from a phase II study of savolitinib in patients (pts) with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer (GEJ/GC)
Authors: Z. Peng, L. Wang, H. Wang, H. Xu, J. Zhang, T. Liu, T. Wu, Y. Yuan, Y. Bai, Z. Liu, B. Liu, E. Li, J. Wang, Q. Pan, X. Jia, Y. Ren, S. Fan, M. Shi, W. Su, L. Shen
Journal: Annals of Oncology (2024)
1504MO Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
Authors: W. Park, C.O’ Connor, J. Chou, C. Schwartz, M. Larsen, A. Varghese, K. Yu, F. Balogun, J. Yang, S. Katz, D. Kelsen, S. Umeda, C. Bandlamudi, N. Riaz, M. Berger, V. Balachandran, D. Peer, M. Capanu, C. Iacobuzio-Donahue, E.M. O'Reilly
Journal: Annals of Oncology (2024)
1450P Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Authors: G.M. Haag, T.O. Goetze, P.C. Thuss-Patience, J. Riera Knorrenschild, S. Lorenzen, N. Homann, T.J. Ettrich, T. Walle, A. Brobeil, M. Ball, M. Schaaf, U. Tenekeci, C. Pauligk, S-E. Al-Batran, A. Stenzinger, A. Stein
Journal: Annals of Oncology (2024)
1433P A phase I/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18.2+/HER2- advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Authors: J. Gong, F. Liu, Z. Jin, M. Zhang, S. Zhang, Y. Zhang, X. Liang, Y. Li, Y. Yang, L. Shen
Journal: Annals of Oncology (2024)
1524P Preliminary phase I safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors
Authors: V. Chung, A.I. Spira, A.C. Pavlick, D. Sommerhalder, B. Ma, V. Hayreh, J. de Jong, J. Funt, S. Kolitz, P. Nair, P.J. King, J. Zhang, J. Kim, A. Yamamura, B. Zeskind, B. Hall, S. Pant
Journal: Annals of Oncology (2024)
1474TiP A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)
Authors: Z. Li, J. Ji, Z. Bu, Y. Wang, Z. Wu, P. Nie, W-L. Li, C. Li, J. You, W. Hu, Y. Zhang, L. Chen, P. Zhao, G. Li, Y. Li, J. Zhuang, J. Shen, D. Feng, J. Fang
Journal: Annals of Oncology (2024)
1601P First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Authors: J. Mateo, E. Castro, A. Rodriguez-Vida, B. Mellado Gonzalez, D.E. Castellano Gauna, M.A. Climent Duran, A. Borque Fernando, M.I. Sáez, B. Herrera Imbroda, A. Font Pous, D. Lorente, J. Planas Morin, A. Vivancos, J. Cardona, J.A. Guerrero, J. Perez-Escuredo, A.J. Zurita Saavedra, J.C. Galceran
Journal: Annals of Oncology (2024)
1444P Nature trumps nurture: Squamous cell carcinoma remains the leading cause of esophageal cancer in Asian-Americans
Authors: S. Gulati, R. Flores, A. Kulshrestha, T. Ivic-Pavlicic, M. Untalan, S. Tuminello, E. Taioli, B. Housman
Journal: Annals of Oncology (2024)
1518P Stereotactic radiotherapy and IMM-101 in patients with oligometastatic pancreatic cancer following FOLFIRINOX: The MEPANC trial
Authors: L. Wismans, S. Kucukcelebi, H. el Haddaoui, M. Moskie, J. Nuyttens, M. Homs, C. van Eijck
Journal: Annals of Oncology (2024)
1562P The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Authors: A. Lepland, M. Tamm, P. Padrik, A. Paas, K. Kruuv-Käo, S. Sõber, L. Roht, K. Ojamaa, S. Pajusalu, A. Padrik, J. Pindmaa, K. Luga, L. Rootslane, A. Ilves, S. Ulp, K. Kallak, A-T. Tihamäe, L. Leitsalu, N. Tõnisson
Journal: Annals of Oncology (2024)
1434P Impact of subsequent anti-tumor therapies in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma receiving fruquintinib (F) plus paclitaxel (PTX) or placebo plus PTX in FRUTIGA study
Authors: R-H. Xu, F. Wang, L. Shen, W. Guo, T. Liu, J. Li, S. Qin, Y. Bai, Z. Chen, J. Wang, Y. Pan, Y. Shu, F. Zhao, Y. Cheng, F. Ye, K. Gu, T. Zhang, H. Pan, P. Tan, W. Su
Journal: Annals of Oncology (2024)
1467P Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study
Authors: J. Chai, L. Wang, L. Liu, B. Liu, D. Sun
Journal: Annals of Oncology (2024)
1443P Association between fruquintinib-induced hypertension and clinical outcomes from FRUTIGA, a phase III study of fruquintinib plus paclitaxel in previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Authors: S. Qin, R-H. Xu, F. Wang, L. Shen, W. Guo, T. Liu, J. Li, Y. Bai, Z. Chen, J. Wang, Y. Pan, Y. Shu, F. Zhao, Y. Cheng, F. Ye, K. Gu, T. Zhang, H. Pan, Q. Liu, S. Fan
Journal: Annals of Oncology (2024)
1525P Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Authors: J.T. Siveke, M. Sinn, K. Dorman, G.M. Siegler, T. Seufferlein, J. Trojan, D.T. Waldschmidt, A.O. Koenig, D. Schipp, S-T. Liffers, V. Kunzmann
Journal: Annals of Oncology (2024)
1539MO Oncologists’ voices in time of crisis: Findings from the ESMO Resilience Task Force survey series on how members can be helped and supported – A qualitative analysis
Authors: C. Hardy, E. Thorne, M. O'Connor, M.E. Elez Fernandez, K.V. Kamposioras, K. Punie, C. Oing, K. Murali, J.B.A.G. Haanen, K.H.J. Lim, S. Banerjee
Journal: Annals of Oncology (2024)
1527P GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)
Authors: S. Kobayashi, A. Ohba, M. Ozaka, J. Mizusawa, T. Okusaka, T. Yamashita, M. Ikeda, I. Yasuda, K. Sugimori, N. Sasahira, K. Ikezawa, I. Miki, N. Okano, N. Mizuno, M. Furukawa, H. Shirakawa, Y. Sano, H. Katayama, J. Furuse, M. Ueno
Journal: Annals of Oncology (2024)
1423P Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial
Authors: E. Elimova, J.A. Ajani, H.A. Burris, C.S. Denlinger, S. Iqbal, Y-K. Kang, J.H. Kim, K-W. Lee, B. Lin, R. Mehta, D-Y. Oh, S.Y. Rha, Y.M. Seol, C. Xie, P. Garfin, G.Y. Ku
Journal: Annals of Oncology (2024)
1514P A prospective, single-center, randomized, controlled, evaluator-blinded, feasibility clinical trial for efficacy and safety of a non-tissue destructive compact focused ultrasound system with neoadjuvant FOLFIRINOX in locally advanced or borderline resectable pancreatic cancer
Authors: J.Y. Lee, S.H. Lee, J-Y. Jang, D.H. Lee, S.Y. Kang, D.H. Park, I.R. Cho, W.H. Paik
Journal: Annals of Oncology (2024)
1471TiP MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
Authors: Z.A. Wainberg, E. Van Cutsem, K. Shitara, Y.Y. Janjigian, D-Y. Oh, J. Xu, S. Wu, S. Bhaumik, P. Bhagia, J. Tabernero
Journal: Annals of Oncology (2024)
1476O Haloperidol and lorazepam for agitated delirium in patients with advanced cancer: A multicenter, double-blind, randomized clinical trial (RCT)
Authors: D. Hui, A. De La Rosa, J-S. Tsai, S-Y. Cheng, D. Urbauer, E. DelFabbro, A. Kuzhiyil, A. Azhar, M. Tang, K. Rowe, T. Nguyen, C-A. Yao, H-L. Huang, J-K. Peng, W-Y. Hu, S. Admane, R. Dev, P. Bramati, S. Shete, E. Bruera
Journal: Annals of Oncology (2024)
1448P IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Authors: C. de la Fouchardiere, A. Zaanan, R. Cohen, S.M. Le Sourd, D. Tougeron, E. Soularue, O. Dubreuil, N. Williet, E. Samalin-Scalzi, G. Piessen, V. Hautefeuille, M. Jary, M. Ben Abdelghani, L. Evesque, P. Rochigneux, E. Blanc, F. Bibeau, A. DeMontfort, C. Coutzac
Journal: Annals of Oncology (2024)
1466P Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Data update from a phase II single-arm study
Authors: F. Wang, C. Zhao, J. Xia, Z. Liu, X. Meng, Z. Shan, J. Jiang, X. Liu, H. Li, J. Sun, C. Ding, H. Zhang, W. Liang, J. Wang, C. Ren, Z. Wang, X. Yang, S. Li
Journal: Annals of Oncology (2024)
1427P Predicting overall survival and prognostic indicator genes in esophagogastric cancer patients using machine learning and bioinformatics analysis
Authors: N-K. Viet-Nhi, P-Y. Chen, N. Kieu Viet Nhu, L. Nguyen Quoc Khanh, M-K. Tsao, M-Q. Tran, T. Vu Cong, H. Tseng, S-H. Hung
Journal: Annals of Oncology (2024)
1447P Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Authors: D. Tougeron, L. Mineur, A. Zaanan, M. Kadi, C. Poisson Ligeza, V. Bourgeois, J. Martin-Babau, A. Fadin, V. Jestin, V. Le Brun-Ly, O. Dubreuil, F. Khemissa, E. Thimonier, O. Bouche, A. Lievre, F. Di Fiore, T. Lecomte, J. Desrame, C. Lepage, V. Hautefeuille
Journal: Annals of Oncology (2024)
1435P Immunomodulatory effects and improved survival of PG2 plus preoperative chemoradiotherapy in patients with locally advanced esophageal cancer
Authors: L-M. Mok, W-C. Huang, H-C. Lin, Y-J. Chen, M-L. Chan, Y-L. Lai, T-W. Huang, P-Y. Chang, Y-F. Su, C-Y. Liu, C-H. Hsieh, C.J. Teng, C-Y. Wu, C-S. Chung, L-S. Wang, J-T. Tsai, C-T. Yeh, T-H. Tsai
Journal: Annals of Oncology (2024)
1436P Better overall survival of male versus female patients with advanced gastric adenocarcinoma
Authors: M. Pan, J. Stover, A. Dang, M. Tong, T. Huang, C. Jiang, J. Bien, L. Habel, S.P. Thomas, A. Pinto, E. Chung, N. Achacoso, P. Tse
Journal: Annals of Oncology (2024)
1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Authors: L. Chang, Z. Lu, Y. Ji, M. Sun, Q. Wen, S.G. Gao, X.L. Ma, J. Zhu, D. Zhong, Q. Guo, S. Xiao, H. Wang, H. Zhu, Y. Zhu, L. Shen
Journal: Annals of Oncology (2024)
1453P A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Authors: N. Bi, F. Liu, Y. Hu, W. Wang, W. Liu, R. Liu, Y. Liu, P. Zhang, C. Zhao, J. Chen, L. Luo, Z. Huang, M. Gu, S. Lu, X. Song, T. Zhao, Y. Wang, H. Liang, J. Xu
Journal: Annals of Oncology (2024)
1430P Impact of menadione supplementation in the treatment of patients with metastatic gastric cancer: A randomized phase II clinical trial
Authors: F.C.A.D. Moraes, D. Feio Da Costa, T. Melgaço, G.D.N.L. Pereira, R.D.S.M. Pereira, E.R.N. Macedo, S.D.S.N. Hoshino, D.Q. Calcagno, P.P.D. Assumpção, R.M.R. Burbano
Journal: Annals of Oncology (2024)
1437P Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Authors: M. Cruz-Correa, D-Y. Oh, K. Kato, J. Tabernero, Y. Bai, J. Shi, K-W. Lee, H. Hirano, D.R. Spigel, L.S. Wyrwicz, R.A. Pazo Cid, A. Cubillo Gracian, L. Li, Y. Xu, T. Sheng, S. Yang, R-H. Xu, M. Moehler
Journal: Annals of Oncology (2024)
1440P Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase II trial
Authors: C. Cheng, W. Yang, S-C. Yeung, S-C. Ma, X. Xing, W. Chen, F. Peng, Y. Bao, X. Wang, S. Zhang, B. Zeng, Z. Liu
Journal: Annals of Oncology (2024)
1519P Real-world evidence on long-term survivors of metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with liposomal irinotecan: NALLONG study
Authors: M. Ueno, C. Yoo, T. Macarulla Mercade, C.B. Westphalen, G. Prager, H. Imaoka, D.T. Waldschmidt, C. Verslype, T. Okusaka, B-Y. Ryoo, F. Hedouin-Biville, B. Chevallier, J-L. van Laethem
Journal: Annals of Oncology (2024)
1470TiP Phase I trial of intraperitoneal infusion of GAIA-102 of NK-Like CD3-negative cells for gastric/pancreatic cancer
Authors: E. Oki, M. Ota, K. Kudo, Y. Zaitsu, R. Nakanishi, Y. Nakashima, K. Ando, Y. Morodomi, T. Yoshizumi, Y. Yonemitsu
Journal: Annals of Oncology (2024)
1477MO A multicenter, randomized controlled trial (RCT) on the efficacy of specialized rehabilitation using the Op-reha guide for terminal cancer patients in palliative care units (PCUs)
Authors: N. Nishiyama, Y. Matsuda, N. Fujiwara, N. Nakajima, K. Narita, S. Oyamada, K. Ariyoshi, K. Ichimaru, T. Kosugi, K. Kushi, I. Owan
Journal: Annals of Oncology (2024)
1428P Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort study
Authors: H.A. Clements, O. Dobrzhanskiy, J. Yang, A. Bausys, L.E. Ferri, G.Y. Ku, E.C. Smyth, T.J. Underwood, R.D. Petty
Journal: Annals of Oncology (2024)
1463P The presence of liver metastases is associated with systemic immune suppression in gastroesophageal cancer
Authors: S. Siegerink, T. van den Ende, D. Kamp, S. Derks, J. Bakker, N. Purcell, E. Boon, G.A. Cirkel, G-J. Creemers, I. Houtenbos, D. Sommeijer, M.M. Streppel, T. Van Voorthuizen, N. Haj Mohammad, T.D. de Gruijl, H.W.M. van Laarhoven
Journal: Annals of Oncology (2024)
1485P Mitigating symptom clusters of patients with metastatic cancer through a remote physical exercise program (EXIO)
Authors: P.G. Bergerot, C.D. Bergerot, J.R. Silva, M.V. França, P.S. Moraes Lages, W.H. Fuzita, A.C. Azeredo, N. Florez, K.H. Schmitz, E. Soto Perez de Celis
Journal: Annals of Oncology (2024)
1456P First in human phase I/II trial of claudin 18.2 ADC RC118 in patients with advanced gastric/gastroesophageal junction cancer
Authors: T. Liu, Y. Yu, S. Ni, B. Liu, N. Li, J. Zhu, X. Liang, X. Liang, M. Xiao, N. Xu, W. Li, X. Qu, J. Wei, L. Yang, X. Li, D. Feng, J. Fang
Journal: Annals of Oncology (2024)
1425P Efficacy and safety of KN026 in combination with chemotherapy in patients (pts) with unresectable or metastatic HER2 positive gastric or gastroesophageal cancers (GC/GEJC) after first-line treatment with a trastuzumab-containing regimen
Authors: J. Xu, J. Zhao, Y. Chen, B. Liu, Y. Du, Y. Cheng, C. Li, J. Zhang, M. Yang, Y. Liu, Y. Bai, S. Li, R. Zhang, F. Ning, Y. Liu, K. Zou, D. Wang, Y. Xie
Journal: Annals of Oncology (2024)
1505P Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts)
Authors: A. Lahusen, T.J. Ettrich, M. Kirchner, K. Kluck, S. Wisser, W. Uhl, M. Kornmann, H. Algül, H. Friess, A.O. Koenig, A. Kleger, J. Schuhbaur, L. Perkhofer, J. Budczies, M.A. Tempero, A. Reinacher-Schick, A. Stenzinger, A. Tannapfel, T. Eiseler, T. Seufferlein
Journal: Annals of Oncology (2024)
1446P Efficacy and safety of cadonilimab combined albumin-paclitaxel, cisplatin and fluorouracil (APF) in neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): Results from the CAPITAL trial
Authors: H. Miao, S. Fu, L. Ruan, Y. Gao, X. Zhu, J. Zhou, W. Fang, H. Xu, L. Liu
Journal: Annals of Oncology (2024)
1483P Prospective observational study to assess the prophylactic effect of topical diclofenac in preventing the development of hand foot syndrome in patients with colorectal and gastric cancer on capecitabine therapy
Authors: O. Yazici, O. Akdogan, S. Eryildiz Yucel, K. Bir Yucel, F. Gurler, A. Özet, B.O. Oksuzoglu, N. Ozdemir, O. Sutcuoglu
Journal: Annals of Oncology (2024)
1465P Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
Authors: T. Wakatsuki, T. Mashima, N. Yamamoto, A. Ooki, H. Shoji, K. Chin, M. Ogura, K. Kiyotani, I. Nakayama, H. Osumi, S. Fukuoka, E. Shinozaki, K. Minashi, H. Hara, K. Takeuchi, H. Seimiya, S. Kitano, N. Boku, K. Yamaguchi, D. Takahari
Journal: Annals of Oncology (2024)
1451P Neoadjuvant and adjuvant pembrolizumab (pembro) + chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study
Authors: K. Shitara, S.Y. Rha, L.S. Wyrwicz, T. Oshima, N. Karaseva, M. Osipov, H. Yasui, H. Yabusaki, S. Afanasyev, Y-K. Park, S-E. Al-Batran, T. Yoshikawa, P.E. Yanez Weber, M. Di Bartolomeo, S. Lonardi, Y. Guan, A. Valderrama, C-S. Shih, X. Fang, Y-J. Bang
Journal: Annals of Oncology (2024)
1489P Factors influencing adherence to electronic patient-reported outcomes in palliative cancer care
Authors: S.A. Gomes, F. Sorice, D. Nunes Moura Silva, F. Ramos da Silva Amaral, A.C. Oliveira Goncalves, R.L. Ferrari, R. Peixoto, C. Vogel, M.H. Cruz Rangel da Silva, B.L. Ferrari, C.D. Bergerot
Journal: Annals of Oncology (2024)
1472TiP Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group – The IKF-057/ PRESTO trial
Authors: N. Homann, T.O. Goetze, D. Janke, S. Kubicka, C. Müller, D. Pink, C. Dietrich, S. Ertl, S. Glag, T. Habibzada, S. Neumann, A. West, U. Tenekeci, C. Kopp, C. Pauligk, S-E. Al-Batran
Journal: Annals of Oncology (2024)
1464P Chemo-radiation alone associated with higher risk of death compared to chemo-radiation plus surgery in esophageal squamous cell carcinoma
Authors: B. Housman, S. Gulati, A. Kulshrestha, M. Untalan, T. Ivic-Pavlicic, S. Tuminello, E. Taioli, R. Flores
Journal: Annals of Oncology (2024)
1495P Impact of social isolation on the clinical outcomes in advanced NSCLC patients
Authors: Y. Yamaguchi, T. Yoshida, S. Arakawa, R. Higashiyama, K. Masuda, Y. Shinno, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, E. Satomi, Y. Ohe
Journal: Annals of Oncology (2024)
1737P A comparison of the risk prediction models sarculator and PERSARC in patients with localized soft tissue sarcoma of the extremities and trunk wall
Authors: M.R. Kobbeltvedt, I.V.K. Lobmaier, M. Spreafico, D. Callegaro, R. Miceli, F. Kizilaslan, D. Swanson, I. Hompland, S. Pasquali, M. Fiocco, M. van de Sande, A. Gronchi, K. Boye
Journal: Annals of Oncology (2024)
1500P Caring for carers: The impact of death &amp; dying on doctors-in-training in an Irish tertiary referral hospital
Authors: C. Moloney, C. Steele, C. Forrest, E. Lynch, M. Eltayib, M. Lyons, D. Nuzum, H. O'Sullivan, S. O'Reilly
Journal: Annals of Oncology (2024)
1678P Tunisian couples confronted with breast cancer
Authors: M. Khlif, H. Ben Mansour, H. Mrad, M. Kacem, Y. Zenzri, F. Letaief-Ksontini, A. Mokrani, N. Chraiet, M. Ayadi, K. Meddeb, A. Mezlini, H. Rais
Journal: Annals of Oncology (2024)
1479P Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Authors: P. Gallardo Melo, F. Bosma, A. Urueña, J. Garrillo Cepeda, J. Aguilar-Company, J.C. Tapia, J. Serna i Mont-Ros, L. Maciel Bravo, B. Martin Cullell, O. Mirallas, C. Gianella Blanco, C. Salva de Torres, S. Martinez Peralta, M. Aguado Sorolla, B. Alonso Martínez, S. Eremiev, M. Roca, S. Serradell, J.C. Galceran, P. Gomez Pardo
Journal: Annals of Oncology (2024)
1480P Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Authors: G. Massa, E. Zecca, P. Bracchi, G. Tinè, R. Miceli, A. Pigni, S. Lo Dico, A.T. Caraceni
Journal: Annals of Oncology (2024)
1424P Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial
Authors: A. Gordon, Z. Rajan, C.Y.K. Fong, C. Peckitt, L. Satchwell, S. Cromarty, S. Kidd, K. Piadel, B. Leamon, O. Zhitkov, M. Davidson, J. Thompson, N.R. Maisey, S. Darby, T.S. Waddell, C. Morgan, A. Bradshaw, N. Starling, I. Chau, D. Cunningham
Journal: Annals of Oncology (2024)
1676P Sexuality among Tunisian breast cancer survivors
Authors: N. Issaad, Y. Zenzri, H. Ben Mansour, F. Letaief-Ksontini, M. Ayadi, A. Mokrani, N. Chraiet, H. Rais, K. Meddeb, A. Mezlini
Journal: Annals of Oncology (2024)
1498P Acute myeloid leukemia: Trends in palliative care utilization in hospitalized patients over 65 years old - A national inpatient sample study (2016-2020)
Authors: M. Bermudez, S. Sangam, F. Gallegos, M.C. Tol, Y. Mekonen, A. Newman, I. Fulger
Journal: Annals of Oncology (2024)
1393TiP A phase II/III study to evaluate the optimal dose, safety, and efficacy of livmoniplimab (Livmo) in combination with budigalimab (Budi) plus chemotherapy (CT) vs pembrolizumab (Pembro) plus CT in untreated metastatic non-small cell lung cancer (mNSCLC)
Authors: N. Girard, A. Zer, L.E. Raez, H. Horinouchi, J. Zugazagoitia, X. Chen, S. Jha, C. Ferlini, D. Ngo
Journal: Annals of Oncology (2024)
1406P Interim response evaluation from a phase II study of capecitabine, oxaliplatin, and anti-PD-1 in dMMR esophagogastric cancer (AuspiCiOus trial)
Authors: J. Bos, C.P. Brugman, R. Bennink, L. Verhoeven, H. Westdorp, G-J. Creemers, N. Haj Mohammad, S. Derks, H.W.M. van Laarhoven
Journal: Annals of Oncology (2024)
1357P Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
Authors: H. Yoshioka, K. Mori, N. Ishikawa, H. Hayashi, K. Azuma, Y. Toi, H. Handa, Y. Tamura, H. Akamatsu, H. Daga, M. Yamaguchi, T. Yamaguchi, Y. Sato, N. Yamamoto, K. Nakagawa, T. Kurata
Journal: Annals of Oncology (2024)
1350P Phase I/II trial shows promising efficacy of nadunolimab in combination with platinum doublet as second-line therapy in patients with NSCLC
Authors: A. Paulus, M. Zemaitis, S. Cicenas, Z. Zvirbule, C. Rydberg-Millrud, S. Magnusson, N. Losic, D. Tersago, L.G. Paz-Ares
Journal: Annals of Oncology (2024)
1399TiP Phase III, double-blind study of cannabis sativa extract in pain management and quality of life in patients with metastatic lung cancer: Protocol of a study (IPElife trial)
Authors: D.D.A. Matias, G.M.D.S. Torres, P.H.S.D.E. Melo, T.R.D. Fonseca, M.M.A.D. Melo, K.S.D. Medeiros
Journal: Annals of Oncology (2024)